Standards and guidelines for your daily practice
Get guidance through our new central repository of evidence-based clinical practice guidelines including recommendations, position papers, and standard protocols.
Take a course and get CME credits
Several UEG courses organised by UEG, are accredited by EACCME to award European CME credits.
Prevention of cancer in the gastrointestinal tract and the liver
Learn how to manage patients with pre-neoplastic disorders.
Mistakes in tissue sampling during endoscopy and how to avoid them
Tissue acquisition is the most common manoeuvre performed during endoscopy.
This is the age of liver biomarkers—let the sunshine in!
We are entering a new age of light for noninvasive biomarkers for liver diseases
Much like in the 1969 hit song “The Age of Aquarius”, we are now entering a new age of light when it comes to noninvasive biomarkers for liver diseases. UEG has embraced this new era with an online course that covers current and upcoming biomarkers of steatosis, steatohepatitis, liver fibrosis, hepatocellular carcinoma (HCC) and biliary diseases.In the field of gastroenterology and hepatology, research into noninvasive diagnostics and biomarker discovery has grown exponentially in the past few years. In particular, numerous breakthroughs in the diagnosis of and prediction of prognosis for various acute and chronic liver diseases are now being witnessed. This focus on chronic liver diseases is justified, because they are an increasing source of medical and public health concern worldwide, much of which is due to the lack of early disease biomarkers. A couple of months ago, I had the pleasure of working with Frank Tacke and Jesús Bañales on a new UEG online course “Biomarkers of liver disease”. Our goal was to summarize current diagnostic modalities for nonalcoholic fatty liver disease (NAFLD), from simple steatosis to fibrotic and cirrhotic nonalcoholic steatohepatitis (NASH), HCC and biliary diseases, discuss their main limitations and introduce novel, prospective biomarkers for disease triggering, staging and monitoring. Imaging assessment techniques are well established as noninvasive biomarkers, mitigating the need for an invasive liver biopsy. Our UEG online course covers the imaging tools and technologies already employed for diagnosis and monitoring of NAFLD and, particularly, fibrosis, where they may also have potential for the longitudinal assessment of therapeutic responses.1 It should be noted, however, that having tools that allow diagnosis of NAFLD in its earliest stages is of utmost importance, given the high likelihood of progression to more severe stages, including fibrosis itself. In this regard, the possibility of using extracellular vesicles (EVs) and microRNAs (miRNAs) as novel biomarkers of liver disease is particularly appealing, as the EV cargo, which includes miRNAs, represents a snapshot of the parental liver cell at the time of release and changes immediately according to the pathophysiological status of the liver.2,3 Several miRNAs and EV-related proteins present in serum, bile or urine also display high sensitivity and specificity for the diagnosis of different cholangiopathies. These novel biomarkers may, therefore, be of further use for the early detection of cholangiocarcinoma (CCA),4 particularly considering that, at the moment, only nonspecific biochemical (and/or histological) markers are used in combination with clinical and radiological data for the diagnosis of CCA, according to the expert consensus document recently published by the European Network for the Study of Cholangiocarcinoma.5 As for HCC, diagnosis relies mainly on imaging methods. In fact, only ultrasonography is recommended by the European Association for the Study of the Liver (EASL) and European Organisation for Research and Treatment of Cancer (EORTC) clinical practice guidelines on the management of HCC.6 As such, early HCC diagnosis needs to be improved, as does the ability to identify subgroups of patients who have a different prognosis and response to treatment,7 which could be achieved through EV-based and miRNA-based assays. For instance, specific tumour-associated microparticles (taMPs) have very recently been proposed as novel biomarkers of HCC and CCA.8 As 5 years have passed since the EASL–EORTC guidelines on HCC were published, the next revised version is expected to discuss these and other recent advances in the biomarker field. As a final note, it should be highlighted that the use of EVs and miRNAs as liver disease biomarkers is not without its challenges. Standardization of sample collection, data normalization and analysis, as well as large, independent comprehensive studies in well-characterized patient populations, are needed to help speed its translation to clinical practice. And this is exactly where the sunshine is finally being let in—several large consortiums supported by the European Commission are now addressing these issues, including EPOS (Elucidating Pathways of Steatohepatitis) [http://www.epos-nafld.eu] and, most recently, LITMUS (Liver Investigation: Testing marker Utility in Steatohepatitis) [http://www.litmus-project.eu]. In particular, the primary aim of LITMUS is to bring new diagnostic tests to NAFLD patients and identify those most at risk of developing severe inflammation and liver scarring, by discovering, validating and qualifying better biomarkers. By closing the gap between patients, researchers and industry, such consortiums will undoubtedly have a key role in firmly establishing EVs and microRNAs as noninvasive biomarkers of liver disease in the clinical setting. I do hope this brief summary and the video shared here will motivate you to have a look and try UEG’s new online course “Biomarkers of liver disease”. As for all UEG online courses, access is free when you sign in to your myUEG account. Enjoy! References
- Baues M, Dasgupta A, Ehling J, et al. Fibrosis imaging: Current concepts and future directions. Adv Drug Deliv Rev 2017. Epub ahead of print 3 November 2017. DOI: 10.1016/j.addr.2017.10.013
- Szabo G and Momen-Heravi F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat Rev Gastroenterol Hepatol 2017; 14: 455–466.
- Afonso MB, Rodrigues PM, Simão AL and Castro RE. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med 2016; 5. pii: E30
- Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2017; 66: 1125–1143
- Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13: 261–280.
- European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
- Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut Pub ahead of print 17 November 2017. DOI: 10.1136/gutjnl-2017-315068.
- Julich-Haertel H, Urban SK, Krawczyk M, et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol 2017; 67: 282–292.
ESEGH application opens on Dec 27
See the key dates and get ready for the next European Specialty Examination in Gastroenterology and Hepatology.
Apply now for the Basic Science Course 2018
A course for young PhDs and basic science oriented MDs in the field of GI.
Mistakes in managing H. pylori infection and how to avoid them
Careful practice can overcome declining eradication rates for H. pylori treatment.
The sequelae of Helicobacter pylori infection, a known Group 1 carcinogen, can lead to significant morbidity and mortality worldwide. Billions of people are infected with H. pylori, but the incidence of H. pylori infection is declining in many parts of Europe, with a study from the Netherlands showing a decline in seroprevalence from 48% in subjects born between 1935 and 1946 to 16% in those born between 1977 and 1987.1In recent years, however, eradication rates for H. pylori treatment have been falling, which has led to a large number of patients in the community having inadequately managed infections. Most of the problems that have led to the decline in the success of eradication treatment can be easily overcome through careful practice, supported by the robust framework provided by international guidelines. Careful practice includes the correct management of dyspepsia, the appropriate use of diagnostic tests for H. pylori, acceptable, efficacious treatments that enable good patient compliance and adequate follow up to insure eradication has been achieved in all cases. Here, we discuss the mistakes that are made when managing patients infected with H. pylori. Most of the discussion is evidence based, but where evidence is lacking the discussion is based on the authors’ clinical experience of more than 30 years in the field.
Improve your understanding of Chronic Pancreatitis.
One finding and two surprises
A 65-year-old man presents with a microcytic anaemia and a gastric polyp is found. What is your endoscopic diagnosis?
The gastric polyp seen in the video was discovered in a 65-year-old man who presented with a microcytic anaemia.Case question 1 WHAT IS YOUR ENDOSCOPIC DIAGNOSIS? a) Healing gastric ulcer b) Hyperplastic polyp c) Gastric inflammatory fibroid polyp d) Gastric adenoma e) Gastric cancer
Biomarkers of Liver Disease
Enhance your knowledge of Biomarkers of Liver Disease
Improve your understanding of good polypectomy practice and the use of standardised protocols
Please sign-in and access the BORN module to begin interactive web-based training for endoscopists in the detection and delineation of Barrett´s Oesophagus Related Neoplasia now.
Over the last decade this training module has been developed and validated by members of the International Working Group for the Classification of Oesophagitis.
Find out more
Mistakes in NAFLD and how to avoid them
Management of NAFLD requires a multidisciplinary approach.
Nonalcoholic fatty liver disease (NAFLD) is defined as the accumulation of excess fat (triglyceride) in the liver in the absence of excessive alcohol consumption. Disease severity ranges from simple steatosis (nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), fibrosis, or cirrhosis, with the potential to develop hepatocellular carcinoma (HCC) or require liver transplantation.NAFLD is believed to affect up to 25% of the Western population,1 and is fast becoming the leading reason for liver transplantation worldwide.2 It affects up to 70% of those who are obese,3 and is strongly linked to the metabolic syndrome. Management of NAFLD therefore requires a multidisciplinary approach, not only to identify those patients at risk of progressive liver disease, but also to improve long-term liver and cardiovascular morbidity and mortality. Here, we highlight some of the mistakes commonly made by medical practitioners when managing NAFLD, and give an evidence-based (where possible) or experience-based approach to management of the condition.
Thank you from UEG E-learning!
We wouldn’t be able to provide high-quality, valued content if not for our contributors.